Mercator MedSystems

Executive Summary

Mercator MedSystems is a private medical device company specializing in catheter-based micro-infusion technology for targeted drug delivery. Its lead product, the Bullfrog Micro-Infusion Device, is designed to deliver therapeutics locally to peripheral vasculature during interventional procedures, minimizing systemic side effects. The company is currently conducting clinical trials in deep vein thrombosis (DVT) and below-the-knee peripheral arterial disease (PAD), where precise drug delivery could significantly improve outcomes. Founded in 2001 and headquartered in San Leandro, California, Mercator aims to address unmet needs in cardiovascular and vascular interventions by enabling more effective treatments with reduced toxicity. The Bullfrog platform has the potential to be broadly applicable, but the company remains in the clinical stage without commercialized products. As a development-stage company, Mercator's near-term value hinges on clinical trial results and regulatory progress. Successful data readouts from its DVT and PAD trials would validate the technology and likely spur partnership or funding opportunities. However, the company faces typical risks such as capital constraints, competitive pressure from established drug delivery methods, and regulatory hurdles. The market for targeted interventional therapies is growing, favoring innovative platforms like Bullfrog. Given the early stage and lack of revenue, conviction is moderate but supported by the technology's potential to address large indications. Key upcoming milestones include clinical data releases and enrollment milestones.

Upcoming Catalysts (preview)

• Q4 2026DVT Clinical Trial Data Readout60% success
• Q3 2026Below-the-Knee PAD Trial Enrollment Completion80% success